Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stocks in this Quantisnow insightHealth Care
Historical context for OLMA
Across the 29 sessions after earlier OLMA headlines, the stock closed higher 15 times and lower 14 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | OLMA | SPY |
|---|---|---|---|
| May 26, 2026 | Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer | -1.0% | +0.7% |
| May 22, 2026 | Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting | -2.7% | +0.4% |
| May 20, 2026 | Olema Oncology to Participate in Upcoming Investor Conferences | +6.6% | +1.0% |
| May 12, 2026 | Olema Oncology Reports First Quarter 2026 Financial and Operating Results | -6.0% | -0.2% |
| May 5, 2026 | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +0.1% | +0.8% |
| Apr 30, 2026 | Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors | +1.9% | +1.0% |
Quantisnow market dataNASDAQ
OLMA
Olema Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for OLMA
Full OLMA profile on Quantisnow Follow OLMA and get a push notification the moment its next story breaks.